ReviewThe Lancet. Infectious diseases2022
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.
Review in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Global research trends in tuberculosis drug-resistance mechanisms: a bibliometric and cross-database analysis.Frontiers in microbiology · 2026Pooled it
- Genotypic diversity of multi- and extensively drug-resistant Mycobacterium tuberculosis in Iran: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Droplet digital PCR vs. quantitative real time-PCR for diagnosis of pulmonary and extrapulmonary tuberculosis: systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Global, regional, and national tuberculosis burden associated with six suboptimal dietary exposures from 1990 to 2021: a comparative risk assessment based on the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Structural Prediction and Functional Mechanistic Characterization of Farnesyl Diphosphate Synthase fromACS omega · 2026Article
- Inhalational therapy of pulmonary infectionActa pharmaceutica Sinica. B · 2026Article
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
- Multidrug resistant tuberculosis (MDR-TB) in Eritrea: a retrospective cohort analysis of mortality and associated factors (2013 - 2023).Frontiers in cellular and infection microbiology · 2026Article
- From mutation detection to treatment decisions: CRISPR-enabled diagnostics for drug-resistant tuberculosis.Frontiers in bioengineering and biotechnology · 2026Review
- Optimizing pathological diagnosis of tuberculosis: qPCR outperforms acid-fast staining in formalin-fixed paraffin-embedded tissues and enables resistance profiling.Frontiers in medicine · 2026Article
- Functional and mechanistic characterization of the phosphatidyl-Frontiers in cellular and infection microbiology · 2026Article
- Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- Drug resistance patterns among tuberculosis patients at a tuberculosis designated hospital in Yunnan: a retrospective analysis of the 2013-2022 period.BMC infectious diseases · 2025Article
- Mycobacterium tuberculosis biology, pathogenicity and interaction with the host.Nature reviews. Microbiology · 2025Review
- Clinical standards for antimicrobial stewardship in TB care.IJTLD open · 2025Article
- Being a woman researcher in dangerous laboratories: biosafety level 3 and tuberculosis.Philosophy, ethics, and humanities in medicine : PEHM · 2025Article
- Accuracy of Machine Learning in Identifying Drug Resistance in Tuberculosis: A Systematic Review and Meta-Analysis.Health science reports · 2025Review
- Genomic epidemiology of Mycobacterium tuberculosis in Wales.Scientific reports · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Tuberculosis is second only to COVID-19 as a cause of death from a single infectious agent. In 2020, almost 10 million people were estimated to have developed tuberculosis and it caused 1·5 million deaths. Around a quarter of deaths caused by antimicrobial resistance are due to rifampicin-resistant tuberculosis. Antimicrobial resistance surveillance systems for many bacterial pathogens are still in the early stages of implementation in many countries, and do not yet allow for the estimation of disease burden at the national level. In this Personal View, we present the achievements, challenges, and way forward for the oldest and largest global antimicrobial resistance surveillance system. Hosted by WHO since 1994, the Global Project on Anti-Tuberculosis Drug Resistance Surveillance has served as a platform for the evaluation of the trends in anti-tuberculosis drug resistance for over 25 years at country, regional, and global levels. With an estimated 465 000 incident cases of multidrug-resistant and rifampicin-resistant tuberculosis in 2019, drug-resistant tuberculosis remains a public health crisis. The COVID-19 pandemic has reversed years of progress in providing essential tuberculosis services and reducing disease burden. The number of people diagnosed with drug-resistant tuberculosis has dropped by 22% since before the pandemic, and the number of patients provided with treatment for drug-resistant tuberculosis has dropped by 15%. Now more than ever, closing gaps in the detection of drug-resistant tuberculosis requires investment in research and development of new diagnostic tools and their rollout, expansion of sample transport systems, and the implementation of data connectivity solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.